drugset / Trial / NCT05579275
Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability of JCXH-212 monotherapy and combined with Toripalimab in patients with malignant solid tumors; to determine the maximum tolerated dose (MTD), and to evaluate the dose-limiting toxicity (DLT) of JCXH-212 monotherapy and combined with Toripalimab.
Timeline
- Start
- 2023-02-06
- Primary completion
- 2026-04-28
- Completion
- 2027-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JCXH-212 | Messenger RNA (mRNA) | 100 ug | — |
| Subject | JCXH-212 | Messenger RNA (mRNA) | 200 ug | — |